TELUS-INTERNATIONAL
6.7.2021 12:47:10 CEST | Business Wire | Press release
TELUS International (NYSE and TSX: TIXT), a leading digital customer experience (DCX) innovator that designs, builds and delivers next-generation solutions for global and disruptive brands, today announced the acquisition of Bangalore-based Playment, a leader in data annotation and computer vision tools and services specialized in 2D and 3D image, video and LiDAR (light detection and ranging) - a remote sensing method that uses laser pulses to measure variable distances. The acquisition follows TELUS International’s recent purchase of Lionbridge AI and builds upon the company’s existing deep domain expertise and experience in data annotation, uniquely positioning TELUS International to support technology and large enterprise clients developing AI-powered solutions across a variety of vertical markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005219/en/
“We are very excited to welcome Playment and its highly engaged, world-class product and engineering team to our TELUS International family today. The acquisition will meaningfully accelerate our company’s computer vision capabilities and further bolster our position at the forefront of our global peers with respect to technology innovation, strategy excellence and talent,” said Jeff Puritt, president and CEO of TELUS International. “As one of the key enabling technologies for today’s advanced AI applications, computer vision is among the most revolutionary technologies of our generation with applications across every sector of the economy. The technology has become increasingly valuable to tech firms and the wider market as brands seek to uncover solutions for scenarios that typically require complex human judgement from visual and spatial patterns to solve nuanced business challenges, and build innovative, market-leading smart products and services.”
The computer vision market is forecast to grow from nearly $16 billion in 2021 to more than $50 billion by 2026, according to an analysis by MarketsandMarkets. The technology is disrupting entire industries and driving transformational societal changes from supporting diagnoses in healthcare, to reducing fraud in banking, to improving e-commerce experiences through enhanced visual search features. In agriculture, for example, advanced farming processes powered by computer vision and AI can provide early and accurate detection and diagnosis of plant diseases based on a green-color ratio and other visual cues to reduce losses in crop yields. In harvesting, computer vision and AI systems can automatically grade and sort food items based on trained parameters, for example, in one fruit detection method, color cameras identify apples on trees that are ready to be picked, and additional stereo cameras detect their relative position for automatic harvesting by a robotic vacuum.
“Standing still is not an option for any company in any industry, but developing and powering the innovations of tomorrow requires a large and continuous supply chain of high-quality image and video training data, which also happens to be the most significant bottleneck in AI development,” shared Puritt. “With the addition of Playment’s expertise, ingenuity and proprietary data annotation platform, TELUS International is more strongly positioned than ever to meet our clients’ current and future needs to support their ongoing growth and evolution. As we continue to expand and evolve as a team and as a company, our focus will remain on empowering our clients to meet the accelerated pace of change in today’s digital world and creating long-term value for our clients, shareholders, team members and the communities where we operate.”
Playment was founded in 2015 and received funding from Elevation Capital (formerly SAIF Partners) and Y Combinator in the early phases of its development. Playment provides fully managed data annotation services that include AI strategy consulting and a SaaS-based platform that transforms videos and images into high-quality annotated data to support a broad range of use cases, ranging from computer vision and data categorization to search relevance. With a focus on data security, user experience and efficiency, and by engaging India’s largest on-demand skilled and secure workforce, Playment has established a hyper-productive environment that delivers datasets faster than its competitors.
“We are thrilled to embark upon the exciting journey ahead with the TELUS International team to harness the full potential of computer vision technology and to advance our joint mission of expediting the AI age through our many partnerships with brands around the world,” said Siddharth Mall, co-founder and CEO of Playment. “We look forward to growing our engagements with existing clients and having the opportunity to work with others that are currently supported by TELUS International to demonstrate the art of the possible through our complementary add-on image, video and LiDAR data annotation capabilities and computer vision expertise. By amplifying our R&D efforts to further extend our product leadership in the industry, and leveraging TELUS International’s global presence to accelerate our go-to-market strategy, together we will help drive disruption across all industry verticals, including in automotive, retail, Internet of Things (IoT), financial services, healthcare, and agriculture.”
TELUS International operates in more than 25 countries around the world with a diverse, multilingual team of more than 50,000 team members, and a global AI Community of more than one million trained data annotators and linguists spread across six continents. To learn more about TELUS International AI Data Solutions, visit www.telusinternational.com .
About TELUS International
TELUS International (NYSE and TSX: TIXT) designs, builds and delivers next-generation digital solutions to enhance the customer experience (CX) for global and disruptive brands. The company’s services support the full lifecycle of its clients’ digital transformation journeys and enable them to more quickly embrace next-generation digital technologies to deliver better business outcomes. TELUS International’s integrated solutions and capabilities span digital strategy, innovation, consulting and design, digital transformation and IT lifecycle solutions, data annotation and intelligent automation, and omnichannel CX solutions that include content moderation, trust and safety solutions and other managed solutions. Fueling all stages of company growth, TELUS International partners with brands across high growth industry verticals, including tech and games, communications and media, eCommerce and fintech, healthcare, and travel and hospitality. Learn more at: www.telusinternational.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005219/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom